TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Re-examination Study For Varivax (V210-059 AM2)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants must be vaccinated with VARIVAX as a standard of care~Exclusion Criteria:~* Participants who have been previously vaccinated with VARIVAX~* Contraindication with VARIVAX

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- VARIVAX (Type: None): Attenuated live varicella vaccine was administered in usual practice. Recommended dosing is a single 0.5 mL subcutaneous injection in children 12 months to 12 years of age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, \>=18 and \</= 65 years of age~* HBeAg positive chronic hepatitis B~* Pre-treatment with entecavir for 9-36 months~Exclusion Criteria:~* Antiviral, antineoplastic or immunomodulatory treatment~* Co-infection with active hepatitis A, C or D, or HIV~* Evidence of decompensated liver disease~* History or other evidence of a medical condition associated with chronic liver disease other than viral hepatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Peginterferon alfa-2a + entecavir (Type: EXPERIMENTAL): Participants received PEGASYS® (peginterferon alfa-2a)180 micrograms (mcg) subcutaneously once weekly for 48 weeks, plus entecavir 0.5 milligram (mg) orally once daily for 8 weeks.
- Entecavir (Type: ACTIVE_COMPARATOR): Participants received entecavir 0.5 mg orally once daily for 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Superior Hypogastric Nerve Block for Pain Control Post-uterine Fibroid Embolization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All women with symptomatic fibroids or adenomyosis that have requested and been approved for uterine artery embolization~2. Ability to comply with the requirements of the study procedures~Exclusion Criteria:~1. Patients in whom the vascular anatomy prevents access to the superior hypogastric nerve plexus safely~2. Patients who have known allergy to the anesthetic agent~3. Patients with signs of skin infection at the entry site of the needle used to place the nerve block~4. Patients with signs of infection such as fever~5. Patients with history of inflammatory bowel disease of with signs of colitis~6. Patients with uncorrectable abnormal coagulation status (INR \>1.5 and plt \< 50000 without use of anticoagulation agents)~7. Patients with preexisting conditions, which, in the opinion of the investigator, interfere with the conduct of the study.~8. Patients who are uncooperative, cannot follow instructions, or who are unlikely to comply with follow-up appointments or fill-out the post-procedural pain questionnaires.~9. Patients with a mental state that may preclude completion of the study procedure or is unable to provide informed consent

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control group (Type: SHAM_COMPARATOR): Sham procedure. Subcutaneous injection of 5cc of 1% Xylocaine in the periumbilical region.
- Sup Hypogastric Nerve block group (Type: EXPERIMENTAL): Superior hypogastric nerve block performed during UFE. 20cc of 0.75% Ropivacaine injected at the superior hypogastric nerve plexus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ipratropium Bromide in Peri-Operative COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* All patients must sign an informed consent.~* Male or female patients aged \>= 40 years and \<= 80 years~* All patients must be diagnosed with COPD and must meet the following spirometric criterion: post-bronchodilator forced expiratory volume in 1 second (FEV1) \< 70% of forced vital capacity (FVC) at Screening Visit (Visit 1).~* All patients have relatively stable COPD (i.e. have no COPD exacerbation within 4 weeks prior to Screening Visit).~* All patients are about to receive selective surgical procedures of lobectomy or right bilobectomy or segmentectomy under general anaesthesia, whilst the estimated time of surgical procedures lasts for not less than 2 hours, and the estimated time of general anaesthesia lasts for not less than 3 hours and not longer than 5 hours.~* Patients must be able to perform all study related procedures including technically acceptable pulmonary function tests (PFTs).~Exclusion criteria:~* Patients who need maintenance treatment of bronchodilators (including anticholinergics, ß-agonists, xanthines).~* Patients with a recent history (i.e. six months or less) of myocardial infarction~* Patients with any unstable or life-threatening cardiac arrhythmia requiring intervention or change in drug therapy during the last year~* Patients with symptomatic chronic heart failure (i.e. New York Heart Association functional class III-IV)~* Known narrow angle glaucoma~* Patients with prostatic hyperplasia or bladder neck obstruction with significant symptoms~* Patients with a history of asthma, allergic rhinitis or who have a blood eosinophil count \>= 600 / mm3 (0.6×10\^9/L). A repeat eosinophil count will not be conducted in these patients

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ipratropium (Type: EXPERIMENTAL): 500 mcg four times a day
- placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have completed all dosing requirements in PS0016 without meeting any withdrawal criteria~* Female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception up till 20 weeks after last administration of study drug, and have a negative pregnancy test at Visit 1 (Screening) and immediately prior to first dose~* Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active, up till 20 weeks after the last administration of study medication (anticipated 5 half-lives)~Exclusion Criteria:~* Subjects previously participating in this study~* Subject has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study. Note: For any subject with an ongoing serious adverse event (SAE), or a history of serious infections (including herpes zoster or hospitalizations) in PS0016, the Medical Monitor must be consulted prior to the subject's entry into PS0018~* Subject has any current sign or symptom that may indicate a medically significant infection~* Subject has current clinically active infection with Histoplasma, Coccidiodes, Paracoccidioides, Pneumocystis, tuberculosis (TB), nontuberculous mycobacteria (NTMB),Blastomyces, Aspergillus, or Candidiasis (systemic). Any subject diagnosed with Histoplasmosis, Coccidiodes, Paracoccidioides, Pneumocystis, TB, NTMB, Blastomyces, Aspergillus, or Candidiasis (systemic) during PS0016 is excluded from PS0018 even if treatment has been completed.~* Any subject who meets any withdrawal criteria in the feeder study (PS0016) is excluded from participating in the open-label extension study (PS0018)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Subjects in this cohort will receive dose 1 every four weeks (Q4W) subcutaneously (sc) during the 48-week open-label Treatment Period. There will be an option to increase the dose to dose 2 Q4W at the discretion of the Investigator if the subject's Psoriasis Area and Severity Index (PASI) response is \>=50% to \<75% reduction from the Baseline of PS0016 at Week 12 or later. If the subject's disease is adequately controlled on dose 2 Q4W, they may return to dose 1 Q4W at the discretion of the Investigator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vacuum Suspension: Effects on Tissue Oxygenation, Activity and Fit

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Over 18 and less than 70 years of age,~* Have a below knee amputation involving only one side,~* If the cause of amputation was for traumatic reasons and do not have diabetes or a vascular condition, the amputation must have occurred at least six months ago and the potential subject must have worn a prosthesis for at least four months,~* If the cause of amputation was for diabetes or vascular reasons, the potential subject must have been fit with a prosthesis and have worn it for at least one year,~* Wear the prosthesis for at least 6 hours a day,~* Able to walk without a cane, crutches, or a walker,~* Are moderately active enough to walk at a steady pace for at least 30 minutes.~Exclusion Criteria:~* Have pain in legs or any condition that interferes with walking.~* Have an ulcer on the residual limb,~* If potential subject had an amputation because of a tumor or an infection, no longer have an active tumor or undergoing treatment for a tumor,~* Have fallen within the last 3 months.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: ACTIVE_COMPARATOR): Current clinical practice
- Arm 2 (Type: EXPERIMENTAL): Novel socket system

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1/2 Lyme Vaccine Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Main Inclusion Criteria:~* Subject is 18 to 70 years old at the time of screening~* Subject has an understanding of the study, agrees to its provisions, and gives written informed consent prior to study entry~* Subject is generally healthy, as determined by the investigator's clinical judgment through collection of medical history and the performance of a physical examination~* If female of childbearing potential, presents with a negative urine pregnancy test, and agrees to employ adequate birth control measures for the duration of the study~Additional inclusion criterion for seropositive subjects in Section 2 only:~- Subject is seropositive for Borrelia burgdorferi sensu lato (s.l.) antibodies at study entry~Main Exclusion Criteria:~* Subject has a physician-diagnosed chronic illness related to Lyme borreliosis (LB) or active LB~* Subject has been treated for LB with antibiotics within 3 months of study entry~* Subject had a tick bite within 3 weeks prior to screening or first vaccination~* Subject has a history or active infection with Babesia microti (babesiosis) or Anaplasma phagocytophilum (ehrlichiosis)~* Subject currently has or has a history of significant cardiovascular, respiratory (including asthma), metabolic, neurological, hepatic, rheumatic, autoimmune, hematological, gastrointestinal or renal disorder~* Subject has clinically significant abnormal laboratory values at screening~* Subject currently has or has a history of immunodeficiency~* Subject tests positive for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV)~* Subject has a disease or is currently undergoing a form of treatment or was undergoing a form of treatment within 30 days prior to study entry that could be expected to influence immune response.~* Subject has a history of anaphylaxis or severe allergic reactions~* Subject has received any live vaccine within 4 weeks or inactivated vaccine within 2 weeks prior to vaccination in this study~* Subject is pregnant or lactating at the time of study enrollment~Additional exclusion criterion for subjects in Section 1 and seronegative subjects in Section 2:~- Subject is seropositive for Borrelia burgdorferi sensu lato (s.l.) antibodies at study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Primary vaccination in seronegative subjects (Type: EXPERIMENTAL): None
- Booster vaccination in seronegative subjects (Type: EXPERIMENTAL): None
- Primary + booster vacc. (seronegative + seropositive subjects) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* High cholesterol blood levels (LDL-cholesterol above 100 mg/dL up to 220 mg/dL.~* Triglycerides up to 600 mg/dL.~* History of coronary artery disease (ex.: heart attack, angina), stroke, diabetes or at high risk of such events.~Exclusion Criteria:~* Pregnancy or lactation, use of high statin doses (\>40mg) at baseline, liver or renal problems~* Use of other drugs that would interfere with evaluation of efficacy or cause safety problems~* Uncontrolled hypertension, diabetes or hypothyroidism~* Recent cardiac event of procedure~* High baseline CPK levels

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult male or female of ages 18 to 50 inclusive~2. Body weight \> 50 kg (110 lb.) and body mass index between 18 and 32 kg/m2 inclusive~3. Medically healthy with clinically insignificant findings based on medical history, 12-lead ECG, and physical examination~4. Negative urine pregnancy test in women of childbearing potential~Exclusion Criteria:~1. Previous exposure to pegfilgrastim or filgrastim, or known allergy to PEG (polyethylene glycol)~2. Chemistry and hematology values outside protocol specified range~3. Current or previous cancer, diabetes, or any clinically significant cardiovascular, metabolic, renal, hepatic, gastrointestinal, hematologic, respiratory, dermatological, neurological, psychiatric, or other disorder~4. History of chronic or acute respiratory illness within the past 4 weeks~5. Positive urine drug or alcohol screen or unwillingness to abstain from alcohol or recreational drugs for the duration of study participation~6. No prescription or nonprescription drugs during the study~7. Participation in an investigational clinical study within 30 days prior to screening~8. Known or suspected allergic reaction to latex

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- CHS-1701 (Type: EXPERIMENTAL): CHS-1701 followed by CHS-1701
- Neulasta (Type: ACTIVE_COMPARATOR): Neulasta followed by Neulasta

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of written informed consent before initiation of any study-related procedures~2. Men and women aged 18 to 65 years.~3. A documented clinical diagnosis according to the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision) meeting criteria 296.4x Bipolar I disorder, most recent episode manic, 296.6x Bipolar I disorder, most recent episode mixed, or 296.5x Bipolar I disorder, most recent episode depressed.~4. PSQI total score of \>=5.~5. MADRS total score of \<=12.~6. YMRS total score of \<= 12~7. Female patients of childbearing potential must have a negative urine pregnancy test at enrollment and be willing to use a reliable method of birth control, i.e., double-barrier method, oral contraceptive, implant, dermal contraception, long-term injectable contraceptive, intrauterine device or tubal ligation, during the study.~8. Be able to understand and comply with the requirements of the study, as judged by the investigator.~9. Outpatient status at enrollment.~Exclusion Criteria:~1. Patients with a diagnosis of DSM-IV Axis II disorder which has a major impact on the patient's current psychiatric status.~2. Presence of prohibited medications of antidepressants (including MAOI's) and systemic corticosteroids.~3. Patients with a diagnosis of primary insomnia disorders~4. Patients with a diagnosis of severe chronic obstructive pulmonary disease~5. A clinical finding that is untreated (eg, hypertension, poorly controlled diabetes, angina) or that, in the opinion of the investigator, would be negatively affected by the study medication or that would affect the study medication.~6. Patients with active substance abuse diagnoses (except tobacco abuse).~7. Known history of intolerance or hypersensitivity to ramelteon or to any other component in the tablet.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ramelteon (Type: EXPERIMENTAL): 8 mg
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bismuth for PCAB-based H. Pylori Eradication

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Gastroscopy can be performed~* H. pylori test and pathological analysis can be performed~Exclusion Criteria:~* Age \< 20 or \> 80 years~* Anemia (serum hemoglobin level \< 10 g/dL)~* Severe systemic disease~* Advanced chronic liver disease~* Use of certain medications, including proton pump inhibitors, H2- receptor antagonists, or antibiotics~* History of H. pylori eradication~* Drug allergy to antibiotics~* History of gastric surgery~* Recent history of upper gastrointestinal bleeding

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Non-bismuth group (Type: None): Tegoprazan 50 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid for 14 days
- Bismuth group (Type: None): Tegoprazan 50 mg bid, amoxicillin 1000 mg bid, clarithromycin 500 mg bid, tripotassium dicitrate bismuthate (DENOL) 300 mg bid for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically confirmed solid tumors, Eastern Cooperative Oncology Group (ECOG) 0 or 1~* Patients with acceptable renal, hepatic, and bone marrow function~Exclusion Criteria:~* Symptomatic and/or unstable brain metastases,~* Any cancer treatment within 4 weeks from study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARM A (Type: EXPERIMENTAL): Carboplatin plus PF-01367338
- ARM A EXPANSION (Type: EXPERIMENTAL): Carboplatin plus PF-01367338

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete